{"id":55992,"date":"2024-01-18T18:04:39","date_gmt":"2024-01-18T18:04:39","guid":{"rendered":"https:\/\/cdhf.staging.not4prod.com\/?p=55992"},"modified":"2024-01-29T21:28:14","modified_gmt":"2024-01-29T21:28:14","slug":"using-the-lyfemd-app-to-help-manage-metabolic-dysfunction-associated-steatotic-liver-disease-masld","status":"publish","type":"post","link":"https:\/\/cdhf.ca\/en\/using-the-lyfemd-app-to-help-manage-metabolic-dysfunction-associated-steatotic-liver-disease-masld\/","title":{"rendered":"Using the LyfeMD app to help Manage Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)"},"content":{"rendered":"\n

MASLD stands for Metabolic Dysfunction-Associated Steatotic Liver Disease<\/a>, formally known as Non-Alcoholic Fatty Liver Disease (NAFLD).1<\/sup> It’s a condition characterized by the accumulation of fat in the liver cells of people who drink little to no alcohol. MASLD is becoming increasingly common and is often associated with obesity, insulin resistance, and metabolic syndrome.<\/p>\n\n\n\n

Managing MASLD typically involves lifestyle changes, such as adopting a healthy diet<\/a>, increasing physical activity, and losing weight if necessary. Those with MASLD rarely have liver related symptoms, and commonly this condition is identified by abnormalities seen on blood work, done for routine purposes. Understandably, when confronted with news of liver disease, there are mixed responses of surprise, fear, and many questions about the diagnosis. If this is you, you may wonder what this diagnosis means, how and if it can be treated, and next steps of action. <\/p>\n\n\n\n

People living with overweight or obesity, high blood sugar or high levels of fats in their blood, particularly triglycerides, are at higher risk for developing MASLD. Other risk factors include diet, lower engagement in physical activity, and mental health concerns such as poor mood or depression. Lifestyle management is the cornerstone treatment to improve your liver disease. However, lifestyle treatment is hard without support systems.<\/p>\n\n\n\n

MASLD is a common condition, affecting over 20% of people in Canada and the United States. While it is unsettling to have been diagnosed with liver disease, fortunately, MASLD is treatable<\/a> when it is diagnosed early<\/strong>. With commitment to therapy, it can reduce the risks of progression to advanced liver disease almost completely. <\/p>\n\n\n\n

The LyfeMD app can help!<\/h2>\n\n\n\n

Developed by gastroenterologists, hepatologists and registered dietitians, the lifestyle therapies offered through LyfeMD were all created from evidence-based research as part of Ascend (Alberta\u2019s Collaboration of Excellence for Nutrition in Digestive Disease), which brings together experts from the University of Calgary and University of Alberta led by Dr. Maitreyi Raman out of the Cumming School of Medicine.<\/p>\n\n\n

\n
\"lyfemd